ProfileGDS5678 / 1438357_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 57% 57% 55% 57% 61% 59% 57% 56% 57% 57% 57% 58% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5800859
GSM967853U87-EV human glioblastoma xenograft - Control 23.4707357
GSM967854U87-EV human glioblastoma xenograft - Control 33.4540557
GSM967855U87-EV human glioblastoma xenograft - Control 43.3155655
GSM967856U87-EV human glioblastoma xenograft - Control 53.3929757
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7410961
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6346459
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4380957
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3972456
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4209857
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4636457
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4176657
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5034258
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4590857